%0 Editorial
%T Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?
%A Gargalionis AN
%A Papavassiliou KA
%A Papavassiliou AG
%J Int J Mol Sci
%V 25
%N 12
%D 2024 Jun 7
%M 38928013
%F 6.208
%R 10.3390/ijms25126309
%X Lung cancer has been established as the second most common cancer worldwide (most common cancer in men and second most common cancer in women) and as the leading cause of cancer morbidity among neoplasms [...].